MXPA05009523A - Derivados de quinolina/benzoxazinona y sus usos. - Google Patents

Derivados de quinolina/benzoxazinona y sus usos.

Info

Publication number
MXPA05009523A
MXPA05009523A MXPA05009523A MXPA05009523A MXPA05009523A MX PA05009523 A MXPA05009523 A MX PA05009523A MX PA05009523 A MXPA05009523 A MX PA05009523A MX PA05009523 A MXPA05009523 A MX PA05009523A MX PA05009523 A MXPA05009523 A MX PA05009523A
Authority
MX
Mexico
Prior art keywords
quinolinone
benzoxazinone derivatives
benzoxazinone
derivatives
methods
Prior art date
Application number
MXPA05009523A
Other languages
English (en)
Inventor
Stephen Stabler Russell
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05009523A publication Critical patent/MXPA05009523A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

La invencion proporciona compuestos de formula I (ver formula I) y sales farmaceuticamente aceptables o profarmacos de los mismos, en donde m, p, q, r, A, E, X, Y R1, R4, R5, R6, R7, R8, R9 son como se definieron en la presente. La invencion proporciona tambien metodos para preparar, composiciones que los comprenden y metodos para el uso de los compuestos de formula I.
MXPA05009523A 2003-03-11 2004-03-08 Derivados de quinolina/benzoxazinona y sus usos. MXPA05009523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45357403P 2003-03-11 2003-03-11
PCT/EP2004/002340 WO2004080969A1 (en) 2003-03-11 2004-03-08 Quinolinone / benzoxazinone derivatives and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05009523A true MXPA05009523A (es) 2005-10-18

Family

ID=32990787

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009523A MXPA05009523A (es) 2003-03-11 2004-03-08 Derivados de quinolina/benzoxazinona y sus usos.

Country Status (23)

Country Link
US (2) US6943169B2 (es)
EP (1) EP1603880B1 (es)
JP (1) JP4404893B2 (es)
KR (1) KR100691090B1 (es)
CN (1) CN100455570C (es)
AR (1) AR043510A1 (es)
AT (1) ATE394377T1 (es)
AU (1) AU2004220388B9 (es)
BR (1) BRPI0408204A (es)
CA (1) CA2518403A1 (es)
CL (1) CL2004000450A1 (es)
CO (1) CO5601030A2 (es)
DE (1) DE602004013560D1 (es)
ES (1) ES2305742T3 (es)
HR (1) HRP20050775A2 (es)
MX (1) MXPA05009523A (es)
MY (1) MY135470A (es)
NO (1) NO20054135L (es)
NZ (1) NZ541642A (es)
RU (1) RU2333204C2 (es)
TW (1) TWI289141B (es)
WO (1) WO2004080969A1 (es)
ZA (1) ZA200506831B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
AU2004261582C1 (en) 2003-07-22 2010-01-07 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US7592457B2 (en) * 2004-10-20 2009-09-22 Korea Research Institute Of Chemical Technology 3-aryl-3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
JP2010533187A (ja) * 2007-07-11 2010-10-21 ダウ・コーニング・コーポレイション 薬物を送達するための組成物
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2163541A1 (en) * 2008-09-12 2010-03-17 Bayer Schering Pharma Aktiengesellschaft Piperazine derivatives for binding and imaging amyloid plaques and their use
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN114085179B (zh) * 2021-11-29 2024-05-03 福建科宏生物工程股份有限公司 一种n-乙酰基-5-甲氧基色胺的制备方法
WO2023192430A1 (en) * 2022-03-30 2023-10-05 University Of Florida Research Foundation, Incorported Compounds for treating psychostimulant misuse

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3733321A (en) * 1971-07-06 1973-05-15 Squibb & Sons Inc 1,4-benzothiazin-3-ones
US4078062A (en) * 1976-10-28 1978-03-07 E. R. Squibb & Sons, Inc. Substituted 2H-1,4-benzothiazin-3(4H)-ones
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
NZ501258A (en) * 1997-07-11 2001-07-27 Smithkline Beecham P Benzenesulfonamide compounds with 5HT6 receptor antagonist activity for treating anxiety and/or depression
WO1999050254A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
WO1999050263A1 (en) 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
BR9815784A (pt) 1998-03-31 2000-11-21 Warner Lambert Co Benzoxazinonas/benzotiazinonas como inibidores de protease de serina
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
AU2001236606A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
WO2001057019A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
ATE337780T1 (de) * 2000-11-24 2006-09-15 Smithkline Beecham Plc Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
CN1254469C (zh) * 2001-08-10 2006-05-03 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和性的芳基磺酰基衍生物
US7943639B2 (en) * 2002-06-20 2011-05-17 Proximagen Limited Compounds

Also Published As

Publication number Publication date
CA2518403A1 (en) 2004-09-23
BRPI0408204A (pt) 2006-02-14
MY135470A (en) 2008-04-30
WO2004080969A1 (en) 2004-09-23
EP1603880B1 (en) 2008-05-07
JP4404893B2 (ja) 2010-01-27
ES2305742T3 (es) 2008-11-01
AU2004220388B2 (en) 2009-12-10
JP2006515344A (ja) 2006-05-25
KR100691090B1 (ko) 2007-03-12
DE602004013560D1 (de) 2008-06-19
CO5601030A2 (es) 2006-01-31
CL2004000450A1 (es) 2005-01-07
AU2004220388A1 (en) 2004-09-23
NO20054135L (no) 2005-09-23
ATE394377T1 (de) 2008-05-15
ZA200506831B (en) 2006-06-28
KR20050109078A (ko) 2005-11-17
CN100455570C (zh) 2009-01-28
RU2333204C2 (ru) 2008-09-10
HRP20050775A2 (en) 2006-10-31
TWI289141B (en) 2007-11-01
US20050261308A1 (en) 2005-11-24
NZ541642A (en) 2008-03-28
NO20054135D0 (no) 2005-09-06
AR043510A1 (es) 2005-08-03
EP1603880A1 (en) 2005-12-14
US7476675B2 (en) 2009-01-13
AU2004220388B9 (en) 2010-01-07
US6943169B2 (en) 2005-09-13
US20040186092A1 (en) 2004-09-23
CN1759101A (zh) 2006-04-12
TW200424189A (en) 2004-11-16
RU2005131172A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
MY136824A (en) Substituted benzoxazinones and uses thereof
IL177962A0 (en) Compounds and methods for treating dyslipidemia
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
UA94833C2 (en) Substituted bicyclolactams
DE60214591D1 (en) Pyrazolpyrimidinfungizide
MXPA05007341A (es) Derivados de 2-piperidona como agonistas de prostaglandina.
TW200510317A (en) Caspase inhibitors and uses thereof
HK1159614A1 (en) Caspase inhibitors and uses thereof
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
DK1606242T3 (da) Azidfri fremgangsmåde til fremstilling af 1,2-diaminoforbindelser
PL1831191T3 (pl) Pochodne chromanu i ich zastosowanie jako ligandów receptorów 5-HT
MX2009006334A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona.
MY176860A (en) 7-amino alkylidenyl-heterocyclic quinolones and napthyridones
MY147638A (en) 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MY138826A (en) 2,7-substituted indoles
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
WO2007014839A3 (en) Cathepsin k inhibitors
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
MXPA04000036A (es) Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.
IL194390A0 (en) Heterocyclic gaba alpha subtype selective receptor modulators

Legal Events

Date Code Title Description
FG Grant or registration